Effect of CYP2B6 genotype on the plasma efavirenz exposure in an African HIV woman

被引：0
|
作者：
Le Dauphin, Emmanuelle
Barrail-Tran, Aurelie
Brunet, Anne [1 ]
Bouligand, Jerome [2 ]
Goujard, Cecile [1 ]
Taburet, Anne-Marie
机构：
[1] Univ Hosp Bicetre, Dept Infect Dis, Le Kremlin Bicetre, France
[2] Univ Hosp Bicetre, Dept Pharmacogenet, Le Kremlin Bicetre, France
来源：
PHARMACY WORLD & SCIENCE | 2009年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：331 / 332
页数：2
相关论文
共 50 条
  • [1] Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
    Ngaimisi, E.
    Mugusi, S.
    Minzi, O.
    Sasi, P.
    Riedel, K-D
    Suda, A.
    Ueda, N.
    Janabi, M.
    Mugusi, F.
    Haefeli, W. E.
    Bertilsson, L.
    Burhenne, J.
    Aklillu, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (03) : 406 - 413
  • [2] CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
    Maimbo, Milimo
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Masimirembwa, Collen
    Nakamura, Yusuke
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (03) : 267 - 271
  • [3] CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
    Milimo Maimbo
    Kazuma Kiyotani
    Taisei Mushiroda
    Collen Masimirembwa
    Yusuke Nakamura
    European Journal of Clinical Pharmacology, 2012, 68 : 267 - 271
  • [4] CYP2B6 GENETIC VARIATION AND EFAVIRENZ AUTOINDUCTION INFLUENCES CYP2B6 A ACTIVITY AND EFAVIRENZ EXPOSURE IN HEALTHY VOLUNTEERS
    Metzger, I. F.
    Lu, J. B.
    Kreutz, Y.
    Thong, N.
    Flockhart, D. A.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S80 - S80
  • [5] Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype
    Eniayewu, Oluwasegun
    Akinloye, Abdulafeez
    Shenkoya, Babajide
    Azuka, Uche
    Bolaji, Oluseye
    Adejuyigbe, Ebunoluwa
    Owen, Andrew
    Olagunju, Adeniyi
    PHARMACOGENETICS AND GENOMICS, 2024, 34 (08): : 253 - 260
  • [6] Moderator effect of CYP2B6 genotype in HIV-1 patients with tuberculosis treated with rifampicin and efavirenz
    De la Calle, C.
    Sanchez, A.
    Cordero, M.
    Iglesias, A.
    Luna, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 64 - 64
  • [7] CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women
    Roehrich, Carola R.
    Droegemoeller, Britt I.
    Ikediobi, Ogechi
    van der Merwe, Lize
    Grobbelaar, Nelis
    Wright, Galen E. B.
    McGregor, Nathaniel
    Warnich, Louise
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (06) : 529 - 538
  • [8] Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
    Meng, Xianmin
    Yin, Kang
    Wang, Jiangrong
    Dong, Ping
    Liu, Li
    Shen, Yinzhong
    Shen, Li
    Ma, Qing
    Lu, Hongzhou
    Cai, Weimin
    PLOS ONE, 2015, 10 (06):
  • [9] Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
    Carr, Daniel F.
    la Porte, Charles J. L.
    Pirmohamed, Munir
    Owen, Andrew
    Cortes, Claudia P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) : 1889 - 1893
  • [10] CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
    Griesel, Rulan
    Maartens, Gary
    Chirehwa, Maxwell
    Sokhela, Simiso
    Akpomiemie, Godspower
    Moorhouse, Michelle
    Venter, Francois
    Sinxadi, Phumla
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3902 - E3909
12345